Crizotinib (PF-02341066) reverses multidrug resistance in cancer cells by inhibiting the function of P-glycoprotein. [electronic resource]
Producer: 20121030Description: 1669-83 p. digitalISSN:- 1476-5381
- ATP Binding Cassette Transporter, Subfamily B, Member 1 -- antagonists & inhibitors
- Adenosine Triphosphatases -- metabolism
- Animals
- Antineoplastic Agents -- pharmacology
- Cell Line, Tumor
- Crizotinib
- Doxorubicin -- pharmacokinetics
- Drug Resistance, Multiple -- drug effects
- Drug Resistance, Neoplasm -- drug effects
- Female
- Humans
- Mice
- Mice, Nude
- Neoplasms -- drug therapy
- Paclitaxel -- therapeutic use
- Protein Kinase Inhibitors -- pharmacology
- Pyrazoles -- pharmacology
- Pyridines -- pharmacology
- Rhodamine 123 -- pharmacokinetics
- Tumor Burden -- drug effects
- Xenograft Model Antitumor Assays
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.